Heat shock protein 90 (HSP90) is a critical molecular chaperone that plays a vital role in protein stabilization during cellular stress. This protein assists in refolding denatured proteins and is essential for the functionality of numerous client proteins involved in cancer progression. Because HSP90 impacts multiple oncogenic pathways, it presents an exciting target for therapeutic intervention in cancer treatment.

Understanding HSP90 and Its Role in Cancer
HSP90 is known to stabilize proteins that are often misfolded due to various stress factors. By stabilizing these proteins, HSP90 contributes to the survival of cancer cells, thereby enabling the progression of tumors. Inhibitors of HSP90, particularly those that bind to its ATP binding site, have demonstrated the potential to degrade client proteins via the ubiquitin-proteasome pathway. This degradation disrupts the oncogenic processes, thus providing a pharmacological avenue for anticancer therapy.

The Potential of HSP90 Inhibitors
Inhibitors such as geldanamycin and radicicol have shown promising antitumor effects by inhibiting the ATPase activity of HSP90, leading to client protein degradation. This inhibition can significantly impact all the hallmarks of cancer, making HSP90 a multi-faceted therapeutic target.

High-Throughput Screening (HTS) for HSP90 Inhibitors
Creative Bioarray offers extensive utilizing advanced high-throughput screening (HTS) assays. These assays are designed to evaluate large compound libraries and can identify novel HSP90 inhibitors based on several criteria, including:

Inhibition of ATP hydrolysis by HSP90
Inhibition of HSP90’s capability to refold denatured proteins
Competitive inhibition of ligand binding to the N-terminal ATP binding domain
Depletion of HSP90 client proteins in cultured cells
Through these assays, a multitude of potential HSP90 inhibitors have been identified, which could significantly enhance drug development efforts.

Tailored Services and Expert Support
At Creative Bioarray, our team of experts is dedicated to providing personalized support throughout the screening process. Whether you need IC50 determination, single-point concentration assessments, or follow-up studies using in-house produced proteins, we offer comprehensive services. Our focus on quality results, efficient timelines, and responsive communication ensures that your project is in good hands.

Partnering for Success
Creative Bioarray is committed to partnering with clients to advance their research goals in HSP90 inhibition. We welcome inquiries regarding specific requirements and look forward to collaborating on impactful projects in the field of cancer research.

For more information or to discuss your specific needs in HSP90 screening, please reach out to Creative Bioarray today. Together, we can contribute to the future of cancer therapeutics.